MARKET

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

0.7004
+0.0104
+1.51%
Closed 16:00 12/11 EST
OPEN
0.6900
PREV CLOSE
0.6900
HIGH
0.7101
LOW
0.6898
VOLUME
522.67K
TURNOVER
--
52 WEEK HIGH
1.730
52 WEEK LOW
0.6600
MARKET CAP
104.91M
P/E (TTM)
-1.8971
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of LCTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

LCTX News

  • Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells
  • Business Wire.1d ago
  • Lineage Cell Therapeutics Offers Update On SCiStar Study, OPC1 Spinal Cord Injury Program
  • Benzinga.11/15 13:06
  • Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program
  • Business Wire.11/15 13:00
  • BioTime EPS misses by $0.06, misses on revenue
  • seekingalpha.11/13 02:22

More

Industry

Biotechnology & Medical Research
-0.30%
Pharmaceuticals & Medical Research
+0.07%

Hot Stocks

Name
Price
%Change

About LCTX

Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).
More

Webull offers Lineage Cell Therapeutics Inc (LCTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.